Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in

Shandong Bailong Chuangyuan Bio-Tech Co Ltd
SSE:605016

Watchlist Manager
Shandong Bailong Chuangyuan Bio-Tech Co Ltd Logo
Shandong Bailong Chuangyuan Bio-Tech Co Ltd
SSE:605016
Watchlist
Price: 24.7 CNY 0.2% Market Closed
Market Cap: ¥10.4B
Write Note Create Alert Ask AI
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

Price Targets Summary
Shandong Bailong Chuangyuan Bio-Tech Co Ltd

Wall Street analysts forecast Shandong Bailong Chuangyuan Bio-Tech Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Shandong Bailong Chuangyuan Bio-Tech Co Ltd is 25.19 CNY with a low forecast of 21.6 CNY and a high forecast of 29.4 CNY.

Lowest Forecast
Wall Street Target
21.6 CNY
-13% Downside
Average Forecast
Wall Street Target
25.19 CNY
2% Upside
Highest Forecast
Wall Street Target
29.4 CNY
19% Upside
Lowest
Price Target
21.6 CNY
13% Downside
Average
Price Target
25.19 CNY
2% Upside
Highest
Price Target
29.4 CNY
19% Upside
Shandong Bailong Chuangyuan Bio-Tech Co Ltd Competitors:
Price Targets
PFBC
Preferred Bank
14% Upside
FIGS
Figs Inc
-12% Downside
UBM
Ulisse Biomed Spa
95% Upside
PFBC
Preferred Bank
14% Upside
FIGS
Figs Inc
-12% Downside
UBM
Ulisse Biomed Spa
95% Upside

Revenue
Forecast

22% / Year
Past Growth
24% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss
22% / Year
Past Growth
24% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss

For the last 5 years the compound annual growth rate for Shandong Bailong Chuangyuan Bio-Tech Co Ltd's revenue is 22%. The projected CAGR for the next 3 years is 24%.

What are analyst estimates?

Operating Income
Forecast

23% / Year
Past Growth
31% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
23% / Year
Past Growth
31% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

For the last 5 years the compound annual growth rate for Shandong Bailong Chuangyuan Bio-Tech Co Ltd's operating income is 23%. The projected CAGR for the next 3 years is 31%.

What are analyst estimates?

Net Income
Forecast

24% / Year
Past Growth
33% / Year
Estimated Growth
Estimates Accuracy
-11%
Average Miss
24% / Year
Past Growth
33% / Year
Estimated Growth
Estimates Accuracy
-11%
Average Miss

For the last 5 years the compound annual growth rate for Shandong Bailong Chuangyuan Bio-Tech Co Ltd's net income is 24%. The projected CAGR for the next 3 years is 33%.

What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Shandong Bailong Chuangyuan Bio-Tech Co Ltd's stock price target?
Price Target
25.19 CNY

According to Wall Street analysts, the average 1-year price target for Shandong Bailong Chuangyuan Bio-Tech Co Ltd is 25.19 CNY with a low forecast of 21.6 CNY and a high forecast of 29.4 CNY.

What is Shandong Bailong Chuangyuan Bio-Tech Co Ltd's Revenue forecast?
Projected CAGR
24%

For the last 5 years the compound annual growth rate for Shandong Bailong Chuangyuan Bio-Tech Co Ltd's revenue is 22%. The projected CAGR for the next 3 years is 24%.

What is Shandong Bailong Chuangyuan Bio-Tech Co Ltd's Operating Income forecast?
Projected CAGR
31%

For the last 5 years the compound annual growth rate for Shandong Bailong Chuangyuan Bio-Tech Co Ltd's operating income is 23%. The projected CAGR for the next 3 years is 31%.

What is Shandong Bailong Chuangyuan Bio-Tech Co Ltd's Net Income forecast?
Projected CAGR
33%

For the last 5 years the compound annual growth rate for Shandong Bailong Chuangyuan Bio-Tech Co Ltd's net income is 24%. The projected CAGR for the next 3 years is 33%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 319,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.